Enhancing diagnosis, prognosis, and therapeutic outcome prediction of gliomas using genomics

OMICS A Journal of Integrative Biology

Volumn 16, Issue 3, 2012, Pages 113-122

  Assem, Mahfoud ^a   Sibenaller, Zita ^b   Agarwal, Supreet ^a   Al Keilani, Maha S ^a   Alqudah, Mohammad A Y ^a   Ryken, Timothy C ^c  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; ASTROCYTOMA; CANCER PROGNOSIS; CHROMOSOME 10; CHROMOSOME 13; CHROMOSOME 14; CHROMOSOME 19; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME 20; CHROMOSOME 22; CHROMOSOME 7; CHROMOSOME ANALYSIS; COPY NUMBER VARIATION; CORRELATION ANALYSIS; DNA DETERMINATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOCUS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC MARKER; GENOME ANALYSIS; GLIOBLASTOMA; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

FEMALE; GENOMICS; GLIOMA; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84859788407     PISSN: 15362310     EISSN: 15578100     Source Type: Journal    
DOI: 10.1089/omi.2011.0031     Document Type: Article

References (48)

1. Acharya, C.R., Hsu, D.S., Anders, C.K., Anguiano, A., Salter, K.H., Walters, K.S., et al.. (2008). Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA 299, 1574-1587 (Pubitemid 351482796)
2. Aldape, K., Burger, P.C., and Perry, A. (2007). Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Arch Pathol Lab Med 131, 242-251
3. Bauman, G.S., Ino, Y., Ueki, K., Zlatescu, M.C., Fisher, B.J., Macdonald, D.R., et al.. (2000). Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys 48, 825-830
4. Bello, M.J., Leone, P.E., Vaquero, J., De Campos, J.M., Kusak, M.E., Sarasa, J.L., et al.. (1995). Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int J Cancer 64, 207-210
5. Beroukhim, R., Lin, M., Park, Y., Hao, K., Zhao, X., Garraway, L.A., et al.. (2006). Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays. PLoS Comput Biol 2, e41
6. Cairncross, J.G., Ueki, K., Zlatescu, M.C., Lisle, D.K., Finkelstein, D.M., Hammond, R.R., et al.. (1998). Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90, 1473-1479 (Pubitemid 28482012)
7. Cancer Genome Atlas Research Network. 2008. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068
8. Colman, H., Zhang, L., Sulman, E.P., McDonald, J.M., Shooshtari, N.L., Rivera, A., et al.. (2010). A multigene predictor of outcome in glioblastoma. Neuro Oncol 12, 49-57
9. Cowell, J.K., Lo, K.C., Luce, J., and Hawthorn, L. (2010). Interpreting aCGH-defined karyotypic changes in gliomas using copy number status, loss of heterozygosity and allelic ratios. Exp Mol Pathol 88, 82-89
10. Deorah, S., Lynch, C.F., Sibenaller, Z.A., and Ryken, T.C. (2006). Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results Program, 1973 to 2001. Neurosurg Focus 20, E1
11. Engelhard, H.H., Stelea, A., and Cochran, E.J. (2002). Oligodendroglioma: pathology and molecular biology. Surg Neurol 58, 111-117 (Pubitemid 35365906)
12. Freije, W.A., Castro-Vargas, F.E., Fang, Z., Horvath, S., Cloughesy, T., Liau, L.M., et al.. (2004). Gene expression profiling of gliomas strongly predicts survival. Cancer Res 64, 6503-6510 (Pubitemid 39297907)
13. Fritz, B., Schubert, F., Wrobel, G., Schwaenen, C., Wessendorf, S., Nessling, M., et al.. (2002). Microarray-based copy number and expression profiling in dedifferentiated and pleomorphic liposarcoma. Cancer Res 62, 2993-2998 (Pubitemid 34602383)
14. Giannini, C., Burger, P.C., Berkey, B.A., Cairncross, J.G., Jenkins, R.B., Mehta, M., et al.. (2008). Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol 18, 360-369 (Pubitemid 351782844)
15. Gravendeel, L.A.M., Kouwenhoven, M.C., Gevaert, O., de Rooi, J.J., Stubbs, A.P., Duijm, J.E., et al.. (2009). Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res 69, 9065-9072
16. Gupta, M., Djalilvand, A., and Brat, D.J. (2005). Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma. Anat Pathol 124, 755-768 (Pubitemid 41532511)
17. Hegi, M.E., Diserens, A.C., Gorlia, T., Hamou, M.F., de Tribolet, N., Weller, M., et al.. (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352, 997-1003 (Pubitemid 40349502)
18. Huang, T.T., Sarkaria, S.M., Cloughesy, T.F., and Mischel, P.S. (2009). Targeted therapy for malignant glioma patients: lessons learned and the road ahead. Neurotherapeutics 6, 500-512
19. Jeuken, J.W., Sprenger, S.H., Wesseling, P., Macville, M.V., Von Deimling, A., Teepen, H.L., et al.. (1999). Identification of subgroups of high-grade oligodendroglial tumors by comparative genomic hybridization. J Neuropathol Exp Neurol 58, 606-12 (Pubitemid 29264940)
20. Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., et al.. (2002). International STI571 CML Study Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346, 645-652 (Pubitemid 34815868)
21. Kim, L., Hochberg, F.H., Thornton, A.F., Harsh, G.R. 4th, Patel, H., Finkelstein, D., et al.. (1996). Procarbazine, lomustine and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J Neurosurg 85, 602-607 (Pubitemid 26315193)
22. Kleihues, P., Lubbe, J., Watanabe, K., von Ammon, K., and Ohgaki, H. (1994). Genetic alterations associated with glioma progression. Verh Dtsch Ges Pathol 78, 43-47
23. Kraus, J.A., Koopmann, J., Kaskel, P., Maintz, D., Brandner, S., Schramm, J., et al.. (1995). Shared allelic losses on chrom. 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 54, 91-95
24. Lee, Y., Scheck, A.C., Cloughesy, T.F., Lai, A., Dong, J., Farooqi, H.K., et al.. (2008). Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genomics 1, 52
25. Li, A., Walling, J., Ahn, S., Kotliarov, Y., Su, Q., Quezado, M., et al.. (2009). Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. Cancer Res 69, 2091-2099
26. Lo, K.C., Rossi, M.R., LaDuca, J., Hicks, D.G., Turpaz, Y., Hawthorn, L., et al.. (2007). Candidate glioblastoma development gene identification using concordance between copy number abnormalities and gene expression level changes. Genes Chromosomes Cancer 46, 875-894 (Pubitemid 47435018)
27. McDonald, J.M., See, S.J., Tremont, I.W., Colman, H., Gilbert, M.R., Groves, M., et al.. (2005). The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer 104, 1468-1477 (Pubitemid 41356162)
28. Nakamura, M., Kishi, M., Sakaki, T., Hashimoto, H., Nakase, H., Shimada, K., et al.. (2003). Novel tumor suppressor loci on 6q22-23 in primary central nervous system lymphomas. Cancer Res 63, 737-741 (Pubitemid 36231967)
29. Nigro, J.M., Takahashi, M.A., Ginzinger, D.G., Law, M., Passe, S., Jenkins, R.B., wt al. (2001). Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, real-time quantitative polymerase chain reaction assay. Am J Pathol 158 1253-1262
30. Novellino, L., De Filippo, A., Deho, P., Perrone, F., Pilotti, S., Parmiani, G., et al.. (2008) PTPRK negatively regulates transcriptional activity of wild type and mutated oncogenic bcatenin and affects membrane distribution of b-catenin/ E-cadherin complexes. Cell Signal 20, 872-883
31. Ostman, A., Hellberg, C., and Bohmer, F.D. (2006). Proteintyrosine phosphatases and cancer. Nat Rev Cancer 6, 307-320
32. Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., et al.. (2004). EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101, 13306-13311 (Pubitemid 39209661)
33. Parsons, D.W., Jones, S., Zhang, X., Lin, J.C., Leary, R.J., Angenendt, P., et al.. (2008). An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812
34. Pegram, M.D., Lipton, A., Hayes, D.F., Weber, B.L., Baselga, J.M., Tripathy, D., et al.. (1998) Phase II study of receptorenhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16, 2659-2671 (Pubitemid 28363029)
35. Pelloski, C.E., Lin, E., Zhang, L., Yung, W.K., Colman, H., Liu, J.L., et al.. (2006). Prognostic associations of activated mitogenactivated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res 12, 3935-3941 (Pubitemid 44078078)
36. Pérez-Soler, R., Chachoua, A., Hammond, L.A., Rowinsky, E.K., Huberman, M., Karp, D., et al.. (2004). Determinants of tumor response and survival with erlotinib in patients with nonsmall- cell lung cancer. J Clin Oncol 22, 3238-3247 (Pubitemid 41103678)
37. Perry A. (2001). Oligodendroglial neoplasms: current concepts, misconceptions, and folklore. Adv Anat Pathol 8, 183-199
38. Phillips, H.S., Kharbanda, S., Chen, R., Forrest, W.F., Soriano, R.H., Wu, T.D., et al.. (2006). Molecular subclasses of highgrade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9, 157-173 (Pubitemid 43357943)
39. Reifenberger, J., Reifenberger, G., Liu, L., James, C.D., Wechsler, W., and Collins, V.P. (1994). Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 145, 1175-1190 (Pubitemid 24345665)
40. Rich, J.N., Hans, C., Jones B., Iversen, E.S., McLendon, R.E., Rasheed, B.K., et al.. (2005). Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res 65, 4051-4058 (Pubitemid 40775641)
41. Sarkaria, J.N., Yang, L., Grogan, P.T., Kitange, G.J., Carlson, B.L., Schroeder, M.A., et al.. (2007). Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther 6, 1167-1174 (Pubitemid 46554588)
42. Sathornsumetee, S., and Reardon, D.A. (2009). Targeting multiple kinases in glioblastoma multiforme. Expert Opin Invest Drugs 18, 277-292
43. Smith, J.S., Perry, A., Borell, T.J., Lee, H.K., O'Fallon, J., Hosek, S.M., et al.. (2000). Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18, 636-645 (Pubitemid 30078545)
44. Starr, T.K., Allaei, R., Silverstein, K.A., Staggs, R.A., Sarver, A.L., Bergemann, T.L., et al.. (2009). A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science 323, 1747-1750
45. Tamura, K., and Fukuoka, M. (2005). Gefitinib in non-small cell lung cancer. Expert Opin Pharmacother 6, 985-993 (Pubitemid 40946159)
46. Von Deimling, A., Nagel, J., Bender, B., Lenartz, D., Schramm, J., Louis, D.N., et al.. (1994). Deletion mapping of chromosome 19 in human gliomas. Int J Cancer 57, 676-680 (Pubitemid 24201358)
47. Xu, Y., Tan, L., Grachtchouk, V., Voorhees, J.J., and Fisher, G.J. (2005). Receptor-type protein-tyrosine phosphatase-j regulates epidermal growth factor receptor function. J Biol Chem 280, 42694-42700 (Pubitemid 43049228)
48. Zhu, H., Acquaviva, J., Ramachandran, P., Boskovitz, A., Woolfenden, S., Pfannl, R., et al.. (2009). Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proc Natl Acad Sci USA 106, 2712-2716